TOKYO, June 17, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) announced today that it has decided to terminate the development of the DNA vaccine ASP0892, which is currently in Phase 1 study for peanut allergy. 

As a result of this termination, Astellas will book an impairment loss of ¥21.5 billion as other expenses in the first quarter of fiscal year 2021. 

The impact from this termination is not reflected in Astellas' consolidated financial forecasts for the fiscal year ending March 31, 2022 announced in April 2021


Click below for a copy of the full press release

Contact the Media Relations team
Communications & Investor Relations
Main phone line for Media: +81-3244-3201 
Business hours (JST)
From Monday to Thursday: 8:45 am to 5:45 pm, Friday: 8:45 am to 4:00 pm
(closed on Saturdays, Sundays, national holidays and company holidays)